XBiotech Inc. (XBIT) Stock

XBiotech Inc. (XBIT) is a Healthcare stock trading at $2.29 (as of 2026-08-21), with a market capitalization of $69.82M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

XBiotech Inc. is a biopharmaceutical company that discovers, develops, and commercializes True Human monoclonal antibody therapies. Its pipeline targets inflammatory and infectious diseases, including interleukin-1 alpha–related treatments and a True Human COVID-19 therapy, serving patients with conditions such as inflammatory and infectious disorders.

Valuation — source: SEC EDGAR (first-party)
Price$2.29
Market Cap$69.82M
Price / Book0.54
FCF Yield-34.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock Fund Advisors ($10.26M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSushma Shivaswamy
Employees92
CountryUS
IPO Date2015-04-15

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • iBio, Inc. (IBIO)
  • Pliant Therapeutics, Inc. (PLRX)
  • Rein Therapeutics Inc. (RNTX)
  • Spero Therapeutics, Inc. (SPRO)
  • PMV Pharmaceuticals, Inc. (PMVP)
  • OS Therapies Incorporated (OSTX)
  • MediciNova, Inc. (MNOV)
  • Boundless Bio, Inc. (BOLD)
XBIT earnings history · XBIT institutional & insider holders · XBIT KPIs & operating metrics · XBIT financials · XBIT investor presentations & press releases · XBIT SEC filings · XBIT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.